Moises A Calderon,Pascal Demoly,Roy Gerth van Wijk,Jean Bousquet,Aziz Sheikh,Anthony Frew,Glenis Scadding,Claus Bachert,Hans J Malling,Rudolph Valenta,Beatrice Bilo,Antonio Nieto,Cezmi Akdis,Jocelyne Just,Carmen Vidal,Eva M Varga,Emilio Alvarez-Cuesta,Barbara Bohle,Albrecht Bufe,Walter G Canonica,Victoria Cardona,Ronald Dahl,Alain Didier,Stephen R Durham,Peter Eng,Montserrat Fernandez-Rivas,Lars Jacobsen,Marek Jutel,Jörg Kleine-Tebbe,Ludger Klimek,Jan Lötvall,Carmen Moreno,Ralph Mosges,Antonella Muraro,Bodo Niggemann,Giovanni Pajno,Giovanni Passalacqua,Oliver Pfaar,Sabina Rak,Gianenrico Senna,Gabriela Senti,Erkka Valovirta,Marianne van Hage,Johannes C Virchow,Ulrich Wahn,Nikolaos Papadopoulos

Abstract:Allergy today is a public health concern of pandemic proportions, affecting more than 150 million people in Europe alone. In view of epidemiological trends, the European Academy of Allergy and Clinical Immunology (EAACI) predicts that within the next few decades, more than half of the European population may at some point in their lives experience some type of allergy.Not only do allergic patients suffer from a debilitating disease, with the potential for major impact on their quality of life, career progression, personal development and lifestyle choices, but they also constitute a significant burden on health economics and macroeconomics due to the days of lost productivity and underperformance. Given that allergy triggers, including urbanization, industrialization, pollution and climate change, are not expected to change in the foreseeable future, it is imperative that steps are taken to develop, strengthen and optimize preventive and treatment strategies.Allergen specific immunotherapy is the only currently available medical intervention that has the potential to affect the natural course of the disease. Years of basic science research, clinical trials, and systematic reviews and meta-analyses have convincingly shown that allergen specific immunotherapy can achieve substantial results for patients, improving the allergic individuals' quality of life, reducing the long-term costs and burden of allergies, and changing the course of the disease. Allergen specific immunotherapy not only effectively alleviates allergy symptoms, but it has a long-term effect after conclusion of the treatment and can prevent the progression of allergic diseases.Unfortunately, allergen specific immunotherapy has not yet received adequate attention from European institutions, including research funding bodies, even though this could be a most rewarding field in terms of return on investments, translational value and European integration and, a field in which Europe is recognized as a worldwide leader. Evaluation and surveillance of the full cost of allergic diseases is still lacking and further progress is being stifled by the variety of health systems across Europe. This means that the general population remains unaware of the potential use of allergen specific immunotherapy and its potential benefits.We call upon Europe's policy-makers to coordinate actions and improve individual and public health in allergy by:Promoting awareness of the effectiveness of allergen specific immunotherapyUpdating national healthcare policies to support allergen specific immunotherapyPrioritising funding for allergen specific immunotherapy researchMonitoring the macroeconomic and health economic parameters of allergyReinforcing allergy teaching in medical disciplines and specialtiesThe effective implementation of the above policies has the potential for a major positive impact on European health and well-being in the next decade.

Standardization of clinical outcomes used in allergen immunotherapy in allergic asthma: An EAACI position paper

State-of-the-art in marketed adjuvants and formulations in Allergen Immunotherapy: A position paper of the European Academy of Allergy and Clinical Immunology (EAACI)

EAACI position paper on the clinical use of the bronchial allergen challenge: Unmet needs and research priorities

Challenges in the implementation of the EAACI AIT guidelines: A situational analysis of current provision of allergen immunotherapy

2019 ARIA Care pathways for allergen immunotherapy

Allergen Immunotherapy for the Prevention and Treatment of Asthma

Hot topics in allergen immunotherapy, 2023: Current status and future perspective

Advances and highlights in allergen immunotherapy: On the way to sustained clinical and immunologic tolerance

EAACI: A European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapy

The Role of Mobile Health Technologies in Stratifying Patients for AIT and Its Cessation: The ARIA-EAACI Perspective

Expanding Options in House Dust Mite Allergy Immunotherapy: Optimising Individual Patient Outcomes

Real‐world evidence for the long‐term effect of allergen immunotherapy: current status on database‐derived European studies

Extrapolating Evidence-Based Medicine of AIT Into Clinical Practice in the United States

Allergen immunotherapy in children with respiratory allergic diseases.

Allergen manufacturing and quality aspects for allergen immunotherapy in Europe and the United States: An analysis from the EAACI AIT Guidelines Project

Predicting allergen immunotherapy efficacy based on early maintenance phase response in routine clinical practice

Patient-centered digital biomarkers for allergic respiratory diseases and asthma: The ARIA-EAACI approach - ARIA-EAACI Task Force Report

Immunological Outcomes of Allergen-Specific Immunotherapy in Food Allergy

A critical appraisal on AIT in childhood asthma

Development of Core Outcome Measures sets for paediatric and adult Severe Asthma (COMSA)

High baseline prevalence of atopic comorbidities and medication use in children treated with allergy immunotherapy in the REAl-world effeCtiveness in allergy immunoTherapy (REACT) study